• Aleksandra Petrovic Fabijan, Ali Khalid, Susan Maddocks, Josephine Ho, Timothy Gilbey, Indy Sandaradura, Ruby Cy Lin, Nouri Ben Zakour, Carola Venturini, Bethany Bowring, and Jonathan R Iredell.
• Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW.
• Med. J. Aust. 2020 Apr 1; 212 (6): 279285279-285.

AbstractBacteriophage (phage) therapy is re-emerging a century after it began. Activity against antibiotic-resistant pathogens and a lack of serious side effects make phage therapy an attractive treatment option in refractory bacterial infections. Phages are highly specific for their bacterial targets, but the relationship between in vitro activity and in vivo efficacy remains to be rigorously evaluated. Pharmacokinetic and pharmacodynamic principles of phage therapy are generally based on the classic predator-prey relationship, but numerous other factors contribute to phage clearance and optimal dosing strategies remain unclear. Combinations of fully characterised, exclusively lytic phages prepared under good manufacturing practice are limited in their availability. Safety has been demonstrated but randomised controlled trials are needed to evaluate efficacy.© 2019 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

8 keywords...

hide…